Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections
- PMID: 11803060
- DOI: 10.1016/s0264-410x(01)00457-1
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections
Abstract
ChimeriVax is a live, attenuated recombinant virus constructed from yellow fever (YF) 17D in which the envelope protein genes of YF 17D are replaced with the corresponding genes of another flavivirus. A ChimeriVax vaccine was developed against Japanese encephalitis (JE). A randomized, double-blind, outpatient study was conducted to compare the safety and immunogenicity of ChimeriVax-JE and YF 17D. Six YF immune and six non-immune adults were randomized to receive a single SC inoculation of ChimeriVax-JE (5log(10)PFU), ChimeriVax-JE (4log(10)PFU) or YF-VAX((R)) (5log(10)PFU). Mild, transient injection site reactions and flu-like symptoms were noted in all treatment groups, with no significant difference between the groups. Nearly all subjects inoculated with ChimeriVax-JE at both dose levels developed a transient, low-level viremia which was similar in magnitude and duration to that following YF-VAX). Neutralizing antibody seroconversion rates to ChimeriVax-JE was 100% in the high and low dose groups in both naïve and YF immune subjects; seroconversion to wild-type JE strains was similar or lower than to the homologous (vaccine) virus. Mean neutralizing antibody responses were higher in the ChimeriVax-JE high dose groups (naïve subjects LNI 1.55, PRNT(50) 254; YF immune subjects LNI 2.23, PRNT(50) 327) than in the low dose groups (naïve subjects 1.38, PRNT(50) 128; YF immune subjects LNI 1.62, PRNT(50) 270). JE antibody levels were higher in YF immune than in naïve subjects, dispelling concerns about anti-vector immunity. The safety and immunogenicity profile of ChimeriVax-JE vaccine appears to be similar to that of YF 17D. The new vaccine holds promise for prevention of JE in travelers and residents of endemic countries. The ChimeriVax technology platform is being exploited for development of new vaccines against dengue and West Nile.
Similar articles
-
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Vaccine. 2015. PMID: 25446819 Free PMC article. Review.
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Vaccine. 2010. PMID: 19808029 Review.
-
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.Hum Vaccin. 2006 Mar-Apr;2(2):60-7. doi: 10.4161/hv.2.2.2555. Epub 2006 Mar 15. Hum Vaccin. 2006. PMID: 17012873 Clinical Trial.
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.J Infect Dis. 2003 Oct 15;188(8):1213-30. doi: 10.1086/378356. Epub 2003 Oct 3. J Infect Dis. 2003. PMID: 14551893 Clinical Trial.
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584
Cited by
-
Wolbachia-carrying Aedes mosquitoes for preventing dengue infection.Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015636. doi: 10.1002/14651858.CD015636.pub2. Cochrane Database Syst Rev. 2024. PMID: 38597256 Free PMC article. Review.
-
Isolation of Flaviviruses and Alphaviruses with Encephalitogenic Potential Diagnosed by Evandro Chagas Institute (Pará, Brazil) in the Period of 1954-2022: Six Decades of Discoveries.Viruses. 2023 Apr 10;15(4):935. doi: 10.3390/v15040935. Viruses. 2023. PMID: 37112917 Free PMC article.
-
Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses.Vaccines (Basel). 2021 Oct 22;9(11):1230. doi: 10.3390/vaccines9111230. Vaccines (Basel). 2021. PMID: 34835160 Free PMC article. Review.
-
Japanese Encephalitis Vaccines.Curr Treat Options Infect Dis. 2020;12(4):375-386. doi: 10.1007/s40506-020-00242-5. Epub 2020 Nov 12. Curr Treat Options Infect Dis. 2020. PMID: 33204220 Free PMC article. Review.
-
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.Vaccines (Basel). 2020 Nov 13;8(4):680. doi: 10.3390/vaccines8040680. Vaccines (Basel). 2020. PMID: 33202961 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources